Lipocine Statistics
Total Valuation
Lipocine has a market cap or net worth of $26.69 million. The enterprise value is $5.52 million.
Important Dates
The last earnings date was Thursday, November 7, 2024, before market open.
Earnings Date | Nov 7, 2024 |
Ex-Dividend Date | n/a |
Share Statistics
Lipocine has 5.35 million shares outstanding. The number of shares has increased by 1.56% in one year.
Current Share Class | 5.35M |
Shares Outstanding | 5.35M |
Shares Change (YoY) | +1.56% |
Shares Change (QoQ) | +0.08% |
Owned by Insiders (%) | 2.91% |
Owned by Institutions (%) | 10.24% |
Float | 5.19M |
Valuation Ratios
PE Ratio | n/a |
Forward PE | n/a |
PS Ratio | 3.17 |
Forward PS | 17.55 |
PB Ratio | 1.32 |
P/TBV Ratio | 1.32 |
P/FCF Ratio | n/a |
P/OCF Ratio | n/a |
PEG Ratio | n/a |
Financial Ratio History Enterprise Valuation
EV / Earnings | n/a |
EV / Sales | 0.70 |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 12.97, with a Debt / Equity ratio of 0.01.
Current Ratio | 12.97 |
Quick Ratio | 12.59 |
Debt / Equity | 0.01 |
Debt / EBITDA | n/a |
Debt / FCF | n/a |
Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -19.50% and return on invested capital (ROIC) is -15.79%.
Return on Equity (ROE) | -19.50% |
Return on Assets (ROA) | -14.56% |
Return on Capital (ROIC) | -15.79% |
Revenue Per Employee | $466,054 |
Profits Per Employee | -$238,593 |
Employee Count | 17 |
Asset Turnover | 0.35 |
Inventory Turnover | n/a |
Taxes
In the past 12 months, Lipocine has paid $1,236 in taxes.
Income Tax | 1,236 |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +70.04% in the last 52 weeks. The beta is 1.19, so Lipocine's price volatility has been higher than the market average.
Beta (5Y) | 1.19 |
52-Week Price Change | +70.04% |
50-Day Moving Average | 5.08 |
200-Day Moving Average | 5.28 |
Relative Strength Index (RSI) | 41.13 |
Average Volume (20 Days) | 26,843 |
Short Selling Information
The latest short interest is 75,199, so 1.41% of the outstanding shares have been sold short.
Short Interest | 75,199 |
Short Previous Month | 107,537 |
Short % of Shares Out | 1.41% |
Short % of Float | 1.45% |
Short Ratio (days to cover) | 2.80 |
Income Statement
In the last 12 months, Lipocine had revenue of $7.92 million and -$4.06 million in losses. Loss per share was -$0.77.
Revenue | 7.92M |
Gross Profit | 7.92M |
Operating Income | -5.29M |
Pretax Income | -8.49M |
Net Income | -4.06M |
EBITDA | -5.26M |
EBIT | -5.29M |
Loss Per Share | -$0.77 |
Full Income Statement Balance Sheet
The company has $19.82 million in cash and $153,365 in debt, giving a net cash position of $19.67 million or $3.68 per share.
Cash & Cash Equivalents | 19.82M |
Total Debt | 153,365 |
Net Cash | 19.67M |
Net Cash Per Share | $3.68 |
Equity (Book Value) | 19.12M |
Book Value Per Share | 3.57 |
Working Capital | 18.92M |
Full Balance Sheet Cash Flow
In the last 12 months, operating cash flow was -$4.95 million and capital expenditures -$89,234, giving a free cash flow of -$5.03 million.
Operating Cash Flow | -4.95M |
Capital Expenditures | -89,234 |
Free Cash Flow | -5.03M |
FCF Per Share | -$0.94 |
Full Cash Flow Statement Margins
Gross margin is 100.00%, with operating and profit margins of -66.82% and -51.19%.
Gross Margin | 100.00% |
Operating Margin | -66.82% |
Pretax Margin | -51.18% |
Profit Margin | -51.19% |
EBITDA Margin | -66.39% |
EBIT Margin | -66.82% |
FCF Margin | -98.48% |
Dividends & Yields
Lipocine does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | -1.56% |
Shareholder Yield | -1.56% |
Earnings Yield | -16.11% |
FCF Yield | -19.99% |
Analyst Forecast
The average price target for Lipocine is $10.00, which is 100.40% higher than the current price. The consensus rating is "Strong Buy".
Price Target | $10.00 |
Price Target Difference | 100.40% |
Analyst Consensus | Strong Buy |
Analyst Count | 1 |
Revenue Growth Forecast (5Y) | n/a |
EPS Growth Forecast (5Y) | n/a |
Stock Forecasts Stock Splits
The last stock split was on May 12, 2023. It was a reverse split with a ratio of 0.0588235:1.
Last Split Date | May 12, 2023 |
Split Type | Reverse |
Split Ratio | 0.0588235:1 |
Scores
Lipocine has an Altman Z-Score of -3.97 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.
Altman Z-Score | -3.97 |
Piotroski F-Score | 1 |